UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 61

Sortiert nach

Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies

Journal of hematology and oncology, 2021-08, Vol.14 (1), p.1-130, Article 130

2021

Volltextzugriff (PDF)

Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells

Haematologica (Roma), 2013-09, Vol.98 (9), p.1458-1466

2013

Volltextzugriff (PDF)

TLR4 inactivation protects from graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Cellular & molecular immunology, 2013-03, Vol.10 (2), p.165-175

2013

Volltextzugriff (PDF)

Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack

Cancer biology & therapy, 2011-01, Vol.11 (1), p.58-67

2011

Volltextzugriff (PDF)

A phase I study of a TGF- β receptor I kinase inhibitor YL-13027 in patients with advanced solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3098-3098

2021

Volltextzugriff (PDF)

Single-Arm Phase 1b/2 Trial of the PI3Kδ Inhibitor Linperlisib Combining with Gemox in Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

Blood, 2021-11, Vol.138 (Supplement 1), p.2483-2483

2021

Volltextzugriff (PDF)

A Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.9395-9396

2022

Volltextzugriff (PDF)

The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial

Clinical cancer research, 2023-04, Vol.29 (8), p.1440-1449

2023

Volltextzugriff (PDF)

A Phase1b Clinical Study of the Oral PI3Kδ Inhibitor, Linperlisib, in Patients with B-Cell Lymphomas

Blood, 2021-11, Vol.138 (Supplement 1), p.3576-3576

2021

Volltextzugriff (PDF)

A Phase Ib Study of Linperlisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Blood, 2021-11, Vol.138 (Supplement 1), p.1386-1386

2021

Volltextzugriff (PDF)

Preclinical Evaluation of MAX-40279, a FLT3/FGFR Dual Kinase Inhibitor for Treatment of Acute Myeloid Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.3997-3997

2018

Volltextzugriff (PDF)

A phase Ib study of a PI3K δ inhibitor Linperlisib in patients with relapsed or refractory peripheral T-cell lymphoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.7531-7531

2021

Volltextzugriff (PDF)

A phase Ib study of the PI3K δ inhibitor linperlisib in patients with advanced solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3099-3099

2021

Volltextzugriff (PDF)

Absorption, metabolism, and excretion of [14C]YY-20394, a highly selective PI3K-Delta inhibitor in humans

Xenobiotica, 2022-03, Vol.52 (3), p.254-264

2022

Volltextzugriff (PDF)

Phase 1 clinical trial of the PI3K[delta] inhibitor YY-20394 in patients with B-cell hematological malignancies

Journal of hematology and oncology, 2021-08, Vol.14 (1)

2021

Volltextzugriff (PDF)

Celastrol induces apoptosis in non-small-cell lung cancer A549 cells through activation of mitochondria- and Fas/FasL-mediated pathways

Toxicology in vitro, 2011-08, Vol.25 (5), p.1027-1032

2011

Volltextzugriff (PDF)

A phase I study of a selective PI3Kδ inhibitor YY-20394 in patients with relapsed or refractory B-cell malignancies

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7563-7563

2019

Volltextzugriff (PDF)

Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Blood, 2018-11, Vol.132 (Supplement 1), p.5332-5332

2018

Volltextzugriff (PDF)

Abstract 3251: Blockade of HIF-1 with a small molecule inhibitor WP1066 in melanoma

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3251-3251

2013

Volltextzugriff (PDF)

HHT-Induced Cell Apoptosis Is Associated with Reduction of Survivin mRNA Expression

Blood, 2004-11, Vol.104 (11), p.4364-4364

2004

Volltextzugriff (PDF)

The Elastic Model of a Pile Foundation Horizontal Displacement

2015 Seventh International Conference on Measuring Technology and Mechatronics Automation, 2015, p.1197-1199

2015

Volltextzugriff (PDF)

Finite Layer Method to Calculate the Dynamic Compliance of a Foundation

2015 Seventh International Conference on Measuring Technology and Mechatronics Automation, 2015, p.496-498

2015

Volltextzugriff (PDF)

Triggering of Toll-Like Receptor 4 Expression in Human Multiple Myeloma Promotes Proliferation and Protects the Cells From Immune and Chemotherapy Drug Attack

Blood, 2009-11, Vol.114 (22), p.2843-2843

2009

Volltextzugriff (PDF)

Expression of B7-H1 in Mantle Cell Lymphoma Leads to Inhibition of T Cell Response to Tumor Cells

Blood, 2011-11, Vol.118 (21), p.2643-2643

2011

Volltextzugriff (PDF)

Role of TLR4 In Acute Gvhd After Allogenetic Hematopoietic Stem Cell Transplantation

Blood, 2010-11, Vol.116 (21), p.2538-2538

2010

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(60)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Life Sciences & Biomedicine
(13)
Technology
(9)
Area Studies
(7)
Geography
(7)
Materials Science
(7)
Physical Sciences
(7)
Social Sciences
(7)
Urban Studies
(7)
Humans
(6)
Materials Science, Multidisciplinary
(6)
Physics
(5)
Physics, Applied
(5)
Animals
(4)
Mice
(4)
Urbanization Development
(4)
Apoptosis
(3)
Applied Sciences
(3)
Cell Line, Tumor
(3)
Chemistry
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies

Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells

TLR4 inactivation protects from graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack

A phase I study of a TGF- β receptor I kinase inhibitor YL-13027 in patients with advanced solid tumors

Single-Arm Phase 1b/2 Trial of the PI3Kδ Inhibitor Linperlisib Combining with Gemox in Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

A Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma

The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial

A Phase1b Clinical Study of the Oral PI3Kδ Inhibitor, Linperlisib, in Patients with B-Cell Lymphomas

A Phase Ib Study of Linperlisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Preclinical Evaluation of MAX-40279, a FLT3/FGFR Dual Kinase Inhibitor for Treatment of Acute Myeloid Leukemia

A phase Ib study of a PI3K δ inhibitor Linperlisib in patients with relapsed or refractory peripheral T-cell lymphoma

A phase Ib study of the PI3K δ inhibitor linperlisib in patients with advanced solid tumors

Absorption, metabolism, and excretion of [14C]YY-20394, a highly selective PI3K-Delta inhibitor in humans

Phase 1 clinical trial of the PI3K[delta] inhibitor YY-20394 in patients with B-cell hematological malignancies

Celastrol induces apoptosis in non-small-cell lung cancer A549 cells through activation of mitochondria- and Fas/FasL-mediated pathways

A phase I study of a selective PI3Kδ inhibitor YY-20394 in patients with relapsed or refractory B-cell malignancies

Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Abstract 3251: Blockade of HIF-1 with a small molecule inhibitor WP1066 in melanoma

HHT-Induced Cell Apoptosis Is Associated with Reduction of Survivin mRNA Expression

The Elastic Model of a Pile Foundation Horizontal Displacement

Finite Layer Method to Calculate the Dynamic Compliance of a Foundation

Triggering of Toll-Like Receptor 4 Expression in Human Multiple Myeloma Promotes Proliferation and Protects the Cells From Immune and Chemotherapy Drug Attack

Expression of B7-H1 in Mantle Cell Lymphoma Leads to Inhibition of T Cell Response to Tumor Cells

Role of TLR4 In Acute Gvhd After Allogenetic Hematopoietic Stem Cell Transplantation

Suchergebnisse filtern